The pre-administration of AVex-73 hydrochloride (ANAVEX2-73) leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with AVex-73 hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The AVex-73 hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by AVex-73 hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections,AVex-73 hydrochloride attenuates the decrease in Ser9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The AVex-73 hydrochloride treatment dose-dependently prevents the Aβ25-35-induced increase in Aβ1-42 content, with a significant effect at the highest dose tested.
|Animal models||Male mice|
|Formulation||physiological saline solution|
|Dosages||100 μL/20 g|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||37.5 mg/mL in DMSO|
Impurities in Oligonucleotide Drug Substances and Drug Products.
Capaldi D, et al. Nucleic Acid Ther. 2017 Dec;27(6):309-322. PMID: 29125795.
Sigma receptor modulators: a patent review.
Collina S, et al. Expert Opin Ther Pat. 2013 May;23(5):597-613. PMID: 23387851.
Photochlor is a lipophilic, second-generation, chlorin-based photosensitizer.
AMPPD is a new biochemistry ultrasensitive alkaline phosphatase substrate.
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make ADC.
Mitapivat is a potent human R-type pyruvate kinase (PKR) inhibitor.
VH-298 is a potent VHL inhibitor that stabilizes HIF-α and elicits a hypoxic response via a different mechanism, with a Kd value of 80 to 90 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.